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Summary
Background and purpose: All cardiac steroids have a similar structure, bind to and inhibit the ubiquitous transmembrane protein Na + , K + -ATPase and increase the force of contraction of heart muscle. However, there are diverse biological responses to different cardiac steroids both at the cellular and at the molecular level. Moreover, we have recently shown that ouabain inhibits digoxin-and bufalin-induced changes in membrane traffic. The present study was designed to test the hypothesis that ouabain also has an inhibitory effect on cardiotoxicity induced by other cardiac steroids.
Experimental approach:
The hypothesis was tested in isolated heart muscle preparations and in an in vivo model of cardiotoxicity in guinea pigs.
Key results:
Ouabain at a low dose attenuated the toxicity induced by bufalin and digoxin in heart muscle preparations. In addition, ouabain at the low dose (91 ng·kg -1 ·hr ), delayed the development of digoxininduced (500 μg·kg -1 ·hr -1 ) cardiotoxicity in anaesthetized guinea pigs, as manifested by delayed arrhythmia and terminal ventricular fibrillation, as well as a reduced heart rate. In addition, as observed with ouabain, the phosphoinositide 3-kinase inhibitor wortmannin (100 μg·kg ) delayed the digoxin-induced arrhythmia in anaesthetized guinea pigs.
Conclusions and Implications:
The present study demonstrates the inhibitory effect, probably through signal transduction pathways, of ouabain on digoxin-and bufalininduced cardiotoxicity in guinea pigs. Further understanding of this phenomenon could be beneficial for increasing the therapeutic window for cardiac steroids in the treatment of chronic heart failure.
Introduction
Cardenolides such as ouabain and digoxin and bufadienolides such as bufalin, as an ingredient of Chan Su extract, were widely used in the Western and Eastern clinical practices for the treatment of atrial fibrillation and heart failure. However,induction of arrhythmia and a narrow therapeutic window limits their therapeutic application (Eichhorn and Gheorghiade, 2002; Wasserstrom and Aistrup, 2005) .
Cardiac steroids bind to and inhibit the ubiquitous transmembrane protein Na (Aydemir-Koksoy, Abramowitz et al., 2001; Haas, Wang et al., 2002) , Ca ++ oscillations (Aizman, Uhlen et al., 2001 ) and changes in intracellular membrane traffic (Rosen, Glukhman et al., 2004) .
The usual explanation for the cardiac steroid-induced increase in heart contractility is that the inhibition of Na + , K + -ATPase by cardiac steroids causes an increase in intracellular Na + which, in turn, attenuates the Na + /Ca ++ exchange activity, resulting in an increased intracellular Ca ++ concentration, and hence increased contractility (Eichhorn et al., 2002) .
It has been suggested that CS-induced arrhythmia and toxicity result from massive Na + -K + ATPase inhibition, leading to intracellular "calcium overload" (Eichhorn et al., 2002; Khatter, Agbanyo et al., 1989) . According to these canonical explanations, all cardiac steroids should have similar effects. However, the effects of different cardiac steroids are diverse. For example, in rodents, despite their similar inotropic effects, ouabain and bufalin, but not digoxin, significantly shortened action potential duration (Kieval, Butler et al., 1988; Ruch, Nishio et al., 2003) ; The LD 50 of ouabain and digoxin in rats is 14 and 32 mg/kg, respectively (Hovevey-Sion and Kaplanski, 1979; Small, McElroy et al., 1971) . However, a decrease in serum K + concentration significantly reduced the minimum lethal dose of digoxin but did not affect that of ouabain (Fricke and Klaus, 1981) ; bufalin produced a significant increase in heart rate (HR) whereas ouabain did not alter it (Pamnani, Chen et al., 1991) . Furthermore, digoxin even reduced cardiac rhythm (Segal, McNamara et al., 2000) ; The infusion of ouabain (Manunta, Hamilton et al., 2000) and bufalin (Pamnani et al., 1991) for several weeks produced hypertension in rats, whereas, digoxin did not exert such an effect (Huang, Kudlac et al., 1999) or even caused a reduction in systemic blood pressure (BP) and prevented ouabain-induced hypertension when given concomitantly (Manunta et al., 2000) .
Cardiac steroid-induced responses at the cellular and molecular levels also vary (for review see, Dvela, Rosen et al., 2007) . For example, human non-gastric H + -and K + -ATPases are inhibited by bufalin, digoxin, and digitoxin but are virtually resistant to digoxigenin and ouabagenin (Modyanov, Pestov et al., 2003) ; digoxin and digitoxin, but not ouabain, are substrates for the P-glycoprotein transporter (Pauli-Magnus, Murdter et al., 2001) ; ouabain and bufalin differentially affected the intracellular signaling protein 14-3-3 in rat lens (McGowan, Russell et al., 1999) ; Finally, we recently demonstrated that digoxin, bufalin and other cardiac steroids induce the accumulation of endocytosed membrane components and cause alterations in intracellular membrane traffic. Ouabain had no effect on intracellular membrane traffic and even antagonized the changes induced by the other cardiac steroids (Feldmann, Glukmann et al., 2007) .
In view of the diversity in the action of the different cardiac steroids, it is reasonable to suggest that their inotropic and/or toxic effects on cardiac muscle may also vary. Since we have observed an antagonistic effect of ouabain on digoxin-induced changes in membrane traffic, a process leading to cellular stress and apoptosis, we hypothesized that ouabain may also protect cardiac cells from toxicity induced by other cardiac steroids.
This hypothesis was tested in guinea-pig isolated heart muscles and in an in vivo model of cardiotoxicity.
Methods

Animals
All animal care and experimental protocols were approved by the Joint Ethics Committee (IACUC) of the Hebrew University and Hadassah Medical Center.. The Hebrew
University is an AAALAC internationally accredited institute. Experiments were performed on 75 male guinea pigs weighing 300-500 g each. The animals were housed according to a 12-hour light/dark cycle and were allowed an acclimatization period of at least 3 days, with normal guinea pig chow and tap water ad libitum.
In vivo experimental protocol
The guinea pigs were anaesthetized with urethane (Sigma; 1. Due to the highly variable response to cardiac steroids in guinea pigs, all experiments were conducted in pairs, i.e. one animal from the control group and the other from a study group were analyzed simultaneously.
Following at least 60 min equilibrium, the animals were treated with digoxin, ouabain and/or wortmannin, as described below, until terminal ventricular fibrillation (VF) occurred. Three end points were evaluated to test the different effects of the tested solutions: 1) the appearance of the first arrhythmia (as the first ventricular premature beat, or a high grade atrio-ventricular block) both in the ECG and arterial pressure records, 2) the occurrence of ventricular tachycardia (VT) or VF in the ECG and 3) the time of death (cessation of cardiorespiratory activity in the ECG, pressure line and respirator) following the VT/VF was also recorded. The time of onset of the three end points was calculated from the start of infusion. To evaluate the different effects of the tested solutions on heart rate (HR) and BP, the lowest values obtained before the first arrhythmia occurred were calculated as an additional end point.
Ex vivo experimental protocol
The animals were killed by cervical dislocation. The hearts were immediately removed into Krebs−Henseleit bicarbonate buffer (composition in mmol·L -1 : 118.4 NaCl, 4.7
KCl, 25 NaHCO 3 , 1.2 KH 2 PO 4 , 2 CaCl 2 , 1.2 MgSO 4 , and 5.5 glucose, pH 7.4). The right and left atria and papillary muscles were excised from the heart, secured with silk thread to a polypropylene tissue holder, and mounted vertically in a 15 mL bath. The nutrient solution was aerated with 95% O 2 /5% CO 2 and maintained at 37 °C. The left atrium and papillary muscles were driven by a pair of platinum electrodes (field stimulation) with a rectangular current pulse (1 Hz, 0.5 ms, about 1.2 × threshold voltage) generated by an electronic stimulator (Master-8, A.M.P.I., Israel and a custom-made isolated current amplifier). The right atrium beat spontaneously. The developed tension was measured isometrically with a force-displacement transducer Experimetria, Hungary) connected to a bridge amplifier (Lablinc, Coulbourn Instruments, PA, USA). The data were displayed and recorded on a PC based PowerLab/16sp system interface using a software Chart v4.2 for Windows (ADIInstruments, Castle Hill, Australia).
Following at least 60 min equilibrium at a resting force of 0.2 and 0.4 gF (for papillary muscle and atria, respectively), the muscles were challenged with digoxin, bufalin and/or ouabain as described below until arrhythmia developed or for at least 90 min. The concentrations of bufalin and digoxin that were used have been shown in preliminary experiments to initiate arrhythmias in more than 90% of the preparations. Ouabain concentrations were chosen as the highest concentration that does not induce increase in muscle contractility. The maximal force amplitude and upward (+dT/dt) and downward force (-dT/dt) development slopes were measured before drug administration (control) and just before the beginning of arrhythmia and calculated as the average of 20 beats.
Membrane preparation and ATPase activity measurements
Crude membranes (P2) from guinea pig heart were prepared as previously described (Haver, Lichtstein et al., 1995) , and kept frozen (-70 o C) until used. Following thawing, the membranes were incubated in Tris-sodium deoxycholate (0.1%) for 30 min.
Membranes were incubated at 37°C with 1 ml of a solution containing 20 mmol·L -1 Tris buffer, pH 7.4, 1 mmol·L -1 EDTA, 100 mmol·L -1 NaCl, 20 mmol·L -1 KCl, 1 mmol·L -1
MgCl 2 , 5 mmol·L -1 NaN 3 , 3 mmol·L -1 ATP, and varying concentrations of digoxin and ouabain. The reactions were terminated by the addition of 1 ml of ice-cold 8% TCA. The inorganic phosphate generated by the ATPase (P i ) was measured using Malachite Green assay (Chan, Delfert et al., 1986) .
Statistics
The values obtained are expressed as the mean ± S.E. of the number of muscles or animals used in each experiment. Results were analyzed using Student's t-test, the MannWhitney test or analysis of variance for comparison between groups, when appropriate, using SPSS 11.5 for windows (SPSS Inc., Chicago, IL). Differences were considered statistically significant at p < 0.05.
Materials
Ouabain, digoxin, bufalin and wortmannin were obtained from Sigma. Other chemicals were also supplied by Sigma or were of the highest quality and purity.
Ouabain and wortmannin were dissolved in Krebs−Henseleit bicarbonate buffer and saline for the ex vivo and in vivo experiments, respectively. Digoxin and bufalin were dissolved initially in 70% ethanol and then diluted in the appropriate solution. The final ethanol concentration did not exceed 0.5% and did not affect any of the parameters measured (data not shown).
Results
Reduction of bufalin-induced arrhythmia by ouabain in guinea pig papillary and atrial muscle
The addition of bufalin to guinea pig papillary muscle (0.4 μmol·L -1 ) or atrium (225 nmol·L -1 ) preparations caused an immediate and significant increase of about 100% in force amplitude, accompanied by a similar increase in +dT/dt and -dT/dt ( Figure 1A-1C) .
Arrhythmias occurred in all the muscle preparations, although the time to first arrhythmia varied between papillary muscle, left atrium and right atrium, as shown in Figure 1B . In contrast, when ouabain (0.4 μmol·L -1 or 30 nmol·L -1 for papillary muscle and atria, respectively) was added together with bufalin, there was a clear delay in the commencement of arrhythmia in papillary muscle (P<0.05) with a trend towards delay in the atria (P<0.07 and P<0.14, for left atrium and right atrium, respectively, Figure 1B ).In the presence of ouabain, most of the papillary muscle preparations did not develop arrhythmia, even after 90 min.
As expected from the delayed arrhythmia, there was also an increase of about 50% in the maximal force amplitude, together with an increase in +dT/dt and -dT/dt, when ouabain and bufalin were applied together, compared with bufalin alone (P < 0.05 Figure 1C ).
There were no significant changes in the chronotropic effect of bufalin on the right atrium when ouabain was added concomitantly (data not shown). Ouabain by itself caused a slight increase of 5-10% in force amplitude, accompanied by a similar increase in +dT/dt and -dT/dt, that continued for more than 90 min without the development of arrhythmias in any preparation (data not shown).
Reduction of digoxin-induced arrhythmia by ouabain in guinea-pig papillary muscle
The addition of digoxin (3.5 μmol·L -1 ) to guinea pig papillary muscle preparations caused an immediate and significant increase of about 150% in force amplitude, which was accompanied by a similar increase in +dT/dt and -dT/dt ( Figure 1D-1F) . Arrhythmias occurred in all the muscle preparations and the time to first arrhythmia varied ( Figure   1E ).  The addition of ouabain (0.4μmo•L -1 ) together with digoxin caused a significant reduction of 30-40% in the inotropic parameters, compared with that obtained using digoxin alone (P < 0.05, Figure 1F ). This reduction was observed despite the trend of delayed arrhythmia (P<0.1, Figure 1E ) in the presence of ouabain and the additive effects of ouabain and digoxin on the force of contraction as mentioned above.
Reduction of digoxin-induced arrhythmias in vivo by ouabain in guinea pigs
Guinea pigs were given a constant infusion of digoxin. Digoxin dose and infusion rate (500 μg·kg However, infusion of ouabain at a higher dose (182 ng·kg -1 ·hr -1 ), which also did not exert any cardiovascular effects when infused alone, did not show any beneficial effect on digoxin-induced toxicity. On the contrary, the time to terminal VF (death) was much shorter (P < 0.05), implying an additive cardiotoxic effect of ouabain and digoxin ( Figure   2 ).
Reduction of digoxin-induced changes in blood pressure (BP) and heart rate(HR) by ouabain in guinea pigs
The effect of digoxin infusion (500 μg·kg ) on BP and HR was bi-phasic. As seen in Figure 3B ). Ouabain at the high dose did not significantly affect HR (data not shown). Ouabain did not affect digoxin-induced changes in BP at either dose ( Figure 3A and data not shown).
Reduction of digoxin-but not ouabain-induced arrhythmias in vivo by wortmannin in guinea pigs
As described above, we recently demonstrated that ouabain inhibits digoxin-induced changes in intracellular membrane traffic Rosen et al., 2004) . A similar inhibition of digoxin-induced changes in membrane traffic was seen following the addition of wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K), implying that this kinase is involved in the inhibition by ouabain. We, therefore hypothesized that wortmannin would similarly inhibit digoxin-induced cardiotoxicity. Indeed, as seen in Figure 4A , the simultaneous infusion of digoxin together with wortmannin (100 μg·kg ) did not delay any of these toxic manifestations ( Figure   4B ).
Differences between ouabain-and digoxin-induced changes in heart rate and blood pressure in guinea pig
The effects of digoxin infusions (500 μg·kg ) caused an elevation in BP only after the first arrhythmia ( Figure 5A , P < 0.05). Moreover, ouabain did not cause a reduction in HR before the occurrence of the first arrhythmia ( Figure 5B , P < 0.05). These differences imply a distinct cardiotoxicity pathway of each of the two steroids. digoxin minus the background activity) was found to be about 3.5 μmol P i ·mg protein -1 ·hr -1 . This result is in an agreement with other studies using the same membrane preparation (Liu, Gable et al., 2007) . As expected, digoxin inhibited, dose-dependently,
Additive inhibition of Na
-ATPase activity at all ouabain concentrations. Notably, these experiments did not reveal any antagonism by ouabain of the inhibitory activity of digoxin.
Discussion and Conclusions
Our study shows for the first time that in the guinea pig, low doses of ouabain effectively inhibited cardiotoxicity induced by other cardiac steroids, such as digoxin and bufalin.
This inhibition was manifested by a delay in the start of arrhythmia induced by bufalin and digoxin in isolated heart muscle preparations (Figure 1 ) and also in vivo by a delay in the appearance of arrhythmia, HR elevation and terminal VF induced by digoxin (Figures   2 and 3 ).
As described in the Introduction, although all cardiac steroids bind to the same receptor, the Na + , K + -ATPase, earlier studies have noted differences in the response of the cardiovascular system to treatment with different cardiac steroids as well as in the cellular and molecular mechanisms affected by these compounds (see Dvela et al., 2007) .
Despite these observations, the vast majority of the literature refers to the two compounds as Digitalis or cardiac steroids, ignoring the dissimilarities between them. We suggest that all cardiac steroids increase the force of contraction of heart muscle via a common mechanism of action. This mechanism presumably includes inhibition of the plasma (Eichhorn et al., 2002; Khatter et al., 1989; Ruch et al., 2003) .
Consequently, as shown in Figure 1C , the increase in the force of contraction by different CS is additive and this may be a consequence of the additive inhibition of Na These findings suggest that experience with ouabain and digoxin treatment in the clinical setting should differ. Indeed, the published reports comparing the beneficial use of digoxin and ouabain for the treatment of angina pectoris show such differences. Whereas digoxin treatment caused worsening of angina (Ahmed, Rich et al., 2006; Fenn and Gilbert, 1932; Harding, Aronow et al., 1973) , ouabain treatment was beneficial (Kern, 1974; Kubicek and Reisner, 1973; Sarre, 1943; Wagenfeld, 1936) . The pharmacodynamic characteristics of the two steroids also differ: iv-administration of ouabain caused a maximal effect after 5 minutes, which lasted for 5-7 hours and then rapidly declined (Sarre, 1943) . The digoxin effect is slower, starting 5-30 min after injection and reaching a maximum only after 1-4 hrs (Eichhorn et al., 2002) . Furthermore, the therapeutic effects of digoxin and ouabain are observed at steady-state plasma concentrations between 0.6 and 2.5 nmol·L -1 (Bauman, Didomenico et al., 2006; Selden and Smith, 1972) . Digoxin toxicity occurs when the plasma level exceeds 2.5 nmol·L -1 , illustrating the narrow therapeutic window of the drug (Bauman et al., 2006) . Information regarding the toxic concentration threshold for ouabain in humans is not available. However, endogenous ouabain was shown to increase to 86.0 ± 27.2 nmol·L -1 in the circulation of athletes following 15 min of exercise, without any toxic manifestations (Bauer, MullerEhmsen et al., 2005) . The relatively lower toxicity of ouabain and its ability to antagonize the toxic effects of digoxin suggest not only that this steroid should be preferred for clinical use but also that it may serve as an antidote for cardiac steroid intoxication. Intriguingly, as described in the monograph by Kern ( 1974) , already in the 1940-50's, before the availability of Fab fragments for treatment of digoxin intoxication, ouabain was effectively used to treat this condition. Furthermore, it was recommended to use digoxin in combination with oral ouabain to lower the former's toxicity (Kern, 1974) .
Those recommendations have disappeared with time, but the present study supports their rationale.
The molecular basis for the diversity in action and antagonism between various CS is not known. They may result from differences in steroid structure, rendering differential binding characteristics and consequently diverse activation of signaling pathways in different cells (see Dvela et al., 2007) . Our experiments, demonstrating that ouabain did not attenuate digoxin-induced inhibition of Na Wortmannin is a fungal metabolite that specifically inhibits PI3K, MAPK, and myosin light-chain kinase. These actions effectively inhibit receptormediated endocytosis in several cell types, including myocytes (Charney, Egnor et al., 2004; Nicola and Straus, 2004; Richards, Rizzoli et al., 2004; Yang and Holman, 2005) .
We previously showed that wortmannin, like ouabain, inhibits cardiac steroid -induced accumulation of endocytosed membranes in NT2 cells (Rosen et al., 2004) . The observation that wortmannin inhibits digoxin-but not ouabain-induced cardiotoxicity (Figure 4 ) suggests that alterations in intracellular membrane traffic are involved in digoxin-induced cardiotoxicity but not in that of ouabain. On the contrary, NunezDuran's group showed that direct inhibition of receptor-mediated endocytosis by cooling or wortmannin, delayed the toxic effect of ouabain in isolated guinea pig heart preparations (Nunez-Duran, Atonal et al., 1996; Nunez-Duran, Riboni et al., 1988) . This apparent contradiction is probably due to differences between the ex vivo and in vivo settings. Moreover, as mentioned above, we observed an elevation in BP following wortmannin infusion together with ouabain, compared with ouabain alone, before the onset of the first arrhythmia. This elevation was greater in the ex vivo perfused heart lacking the neuronal and hormonal effect of other BP regulatory substances. Taking all the evidence together, we propose that part of the cardiotoxicity induced by cardiac steroids stems from their effect on endocytosed membrane traffic. This effect is antagonized by ouabain, resulting in attenuation of the cardiotoxic manifestations of other cardiac steroids.
This study was designed to investigate the relationship between the cardiotoxicity of different cardiac steroids. Our main finding was the inhibitory effect of ouabain on digoxin-and bufalin-induced cardiotoxicity. Further understanding of this phenomenon could prove beneficial for increasing the therapeutic window of cardiac steroids, in the treatment of chronic heart failure. Preparations which did not develop arrhythmia were given an arbitrary value of 90 min.
F. Maximal inotropic effect on papillary muscle following bufalin or digoxin administration in the presence or absence of ouabain at concentrations as in Figure 1E .
The values are expressed as the mean ± S.E (n = 5-12). * = value higer than that obtained in the presence of bufalin alone (P<0.05). ** = value lower than that obtained in the presence of digoxin alone (P<0.05). 
